OncoMatch/Clinical Trials/NCT06593431
Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
Is NCT06593431 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies non-drug interventions for pancreas cancer.
The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
Demonstration of adequate organ function as defined in the table below, all screening labs to be performed within 4 weeks prior to study enrollment
Kidney function
Demonstration of adequate organ function as defined in the table below, all screening labs to be performed within 4 weeks prior to study enrollment
Liver function
Demonstration of adequate organ function as defined in the table below, all screening labs to be performed within 4 weeks prior to study enrollment
Demonstration of adequate organ function as defined in the table below, all screening labs to be performed within 4 weeks prior to study enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06593431 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages